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Abstract 
The human Ether-à-go-go Related Gene (hERG) encodes a potassium channel responsible for 
the cardiac rapid delayed rectifier K+ current, IKr, which regulates ventricular repolarization. 
Loss-of-function hERG mutations underpin the LQT2 form of congenital long QT syndrome. 
This study was undertaken to elucidate the functional consequences of a variant of 
uncertain significance, T634S, located at a highly conserved position at the top of the S6 
helix of the hERG channel. Whole-cell patch-clamp recordings were made at 37oC of hERG 
current (IhERG) from HEK 293 cells expressing wild-type (WT) hERG, WT+T634S and hERG-
T634S alone. When the T634S mutation was expressed alone little or no IhERG could be 
recorded. Co-expressing WT and hERG-T634S suppressed IhERG tails by ~57% compared to 
WT alone, without significant alteration of voltage dependent activation of IhERG. A similar 
suppression of IhERG was observed under action potential voltage clamp.  Comparable 
reduction of IKr in a ventricular AP model delayed repolarization and led to action potential 
prolongation. A LI-COR® based On/In-Cell Western assay showed that cell surface expression 
of hERG channels in HEK 293 cells was markedly reduced by the T634S mutation, whilst total 
cellular hERG expression was unaffected, demonstrating impaired trafficking of the hERG-
T634S mutant. Incubation with E-4031, but not lumacaftor, rescued defective hERG-T634S 
channel trafficking and IhERG density. In conclusion, these data identify hERG-T634S as a 
rescuable trafficking defective mutation that reduces IKr sufficiently to delay repolarization 
and, thereby, potentially produce a LQT2 phenotype. 
 
Keywords: Arrhythmia, hERG, IKr, long QT syndrome, LQTS, rapid delayed rectifier, 
trafficking.  
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1. Introduction 
 
Electrical repolarization determines the duration of ventricular action potentials and, 
thereby, the length of the QT interval on the electrocardiogram. Of the potassium channel 
currents that contribute to ventricular repolarization, the rapid delayed rectifier current, IKr, 
appears to be particularly notable. The human Ether-à-go-go Related Gene (hERG; 
alternative nomenclature KCNH2) encodes channels that mediate IKr [1; 2].  Loss-of-function 
hERG mutations lead to the LQT2 form of congenital long QT syndrome [3; 4], whilst gain-of-
function hERG mutations underpin the SQT1 form of short QT syndrome [5].  Additionally, 
the marked susceptibility of hERG channels to pharmacological blockade strongly implicates 
the channel in cases of acquired (drug-induced) LQTS [3]. Most hERG mutations linked to 
congenital LQT2 are missense mutations, the majority of which impair channel transport 
within the cell (trafficking); misfolded hERG proteins become retained within the 
endoplasmic reticulum, thereby limiting the number of functional channels in the cell 
membrane [4; 6]. Over 1000 hERG variants exist on publicly available databases such as 
ClinVar, but functional data are available for only a fraction of these. 
LQT2 associated mutations in the transmembrane pore region of hERG appear to be 
associated with a higher risk of arrhythmia events than those in other regions of the channel 
[7; 8].  Pathogenicity cannot automatically be assumed, however, as some variants may be 
benign.  Patch clamp used together with a biochemical assay of hERG channel expression 
has been demonstrated to have significant value for classifying hERG variants of uncertain 
significance (VUS) [9; 10].  A threonine residue (T634) at the top of the S6 helix of the hERG 
channel has recently been identified as able to hydrogen-bond with a glutamate (E575) at 
the top of the S5 segment and to comprise part of a hydrogen-bonded network of residues 
that forms a ring around the top of the channel’s selectivity filter [11]. This threonine 
residue is highly conserved amongst potassium channels (Figure 1A). An LQT2 associated 
isoleucine mutation at this position (T634I) has previously been reported to lead to 
defective hERG channel trafficking [6] and a second mutation (T634A) has been reported in 
an adolescent LQTS patient diagnosed by a school-based screening program [12].  The 
present study was undertaken to characterize a novel hERG VUS, T634S, providing the first 
functional data on any mutation at this position in the hERG protein.  The results 
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demonstrate that T634S leads to a marked, but pharmacologically rescuable, trafficking 
defect.  
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2. Materials and Methods 
 
2.1 Identification and production of the T634S hERG mutation 
A  c.1901C>G  base transition, leading to a missense (p.T634S) mutation was reported 
anonymized [13] as a VUS by a regional clinical genetics service. Use of the polymorphism 
phenotyping informatics  tool “PolyPhen-2” (http://genetics.bwh.harvard.edu/pph2/) 
evaluated this mutation as ‘probably damaging’, whilst the “Mutation assessor” tool  
(http://mutationassessor.org/r3/) predicted it to have medium functional impact. The T634S 
hERG and T634S HA-tagged hERG mutations were generated using the QuikChange® II site-
directed mutagenesis kit (Agilent Technologies) and confirmed using Sanger sequencing. 
Further details are given in the online supplementary Methods. 
 
2.2. Electrophysiological recording 
For electrophysiological experiments, HEK 293 cells were transiently transfected with WT 
and/or hERG-T634S cDNAs, with Lipofectamine following the manufacturer’s instructions, 
using CD8 as a marker of successful transfection [14]. The total amount of hERG cDNA 
transfected (1 μg) was kept constant; thus for WT+T634S conditions the amount of each 
construct transfected was half that used when each channel was expressed alone. 
Recordings were made at 37oC using whole cell patch clamp, as described previously [14].  
Further information is given in the online supplementary Methods.  Mathematical modelling 
of the consequences of the reduction in IKr magnitude due to the T634S mutation was 
performed using the O’Hara-Virag-Varro-Rudy human action potential model [15], reducing 
gKr by 57.1% to match experimentally observed reduction in IhERG when the WT and T634S 
hERG channels were co-expressed. 
 
2.3 On/In Cell Western evaluation of hERG expression 
LI-COR® based Cell Surface (CSA) (‘On-Cell’) and Total cellular hERG expression (Total) (‘In-
Cell’) Western assays were combined to evaluate effects of the T634S mutation on hERG 
channel trafficking in HEK 293 cells. The ‘On-Cell’ Cell Surface Assay (CSA) enabled 
quantitative monitoring of the level of hERG channel expression at the cell surface. An 
extracellular epitope was provided by an HA-epitope tag inserted between the S1 and S2 
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transmembrane domains  [16; 17] (see red section in Figure 3Ai). The ‘In-Cell’ Total Assay 
enabled quantitative monitoring of total cellular hERG channel expression in fixed and 
permeabilized cells (see Figure 3Ai). Assays were performed in 48 well assay plates. Each 
well was transfected, using Lipofectamine 2000, with a total of 1 µg of vector DNA. Where 
HA-hERG-WT (WT) and HA-hERG-T634S (T634S) were co-transfected, 500 ng of each vector 
was used (1 µg total). Transfections were performed as detailed in the schematic diagram 
presented in Figure 3Aii. Assays were performed 48 hours after transfection. Compounds 
were applied (E-4031 (5 µM), lumacaftor (5 μM) and DMSO) 24 hours before assay as 
indicated in Figure 3 Aii. Full methodological details are given in the online supplementary 
Methods.  
2.4 Drugs  
E-4031 was obtained from Tocris (Abingdon, UK); a stock solution of 10 mM was made in 
distilled, deionized water. Lumacaftor was a gift from Professor David Sheppard (University 
of Bristol, UK) and was made as a stock solution of 10 mM in DMSO [18]. To evaluate IhERG 
rescue, these compounds were applied at 5 μM for 24 hours before IhERG recording.  Cells were 
washed and kept in drug-free medium for 1-2 hours before recording.  
2.5 Data analysis and statistics 
Data are presented as mean ± standard error of the mean (SEM).  Statistical analysis was 
performed using unpaired t tests, 1-way or 1-way ANOVA with Bonferroni post-hoc test as 
appropriate. Details of the statistical tests used to evaluate significance of results for 
particular experiments are given alongside P values either in the main text or relevant figure 
legend.  
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3. Results and Discussion 
3.1 Effects of the T634S mutation on IhERG during conventional voltage clamp 
IhERG recordings were made using a standard voltage protocol comprised of a 2s 
depolarization from a holding potential of -80 mV to a series of test potentials between -40 
mV and +60 mV  (in 10 mV increments) followed by repolarization to -40 mV, at which 
potential IhERG ‘tail’ magnitude was monitored and subsequently normalized to current 
density (cf [19; 20]). Figures 1Bi-Biii show representative IhERG recordings respectively under 
WT, WT+T634S and T634S conditions. Co-expression of WT with T634S channels (Figure 
1Bii) led to a marked reduction in IhERG amplitude across the range of test potentials 
compared to WT IhERG (Figure 1Bi). When T634S was expressed alone (Figure 1Biii) IhERG ‘tails’ 
were negligible.  Mean normalized tail current data for each expression condition are 
plotted against corresponding test potential in Figure 1C. This shows that IhERG tails were 
suppressed across a wide range of voltages under WT+T634S (heterozygous) conditions 
compared to the WT channel, whilst they were negligible under T634S (homozygous) 
expression conditions. The tail I-V relations for WT and WT+T634S IhERG were fitted with a 
modified Boltzmann equation to yield an activation V
0.5
 for WT IhERG of -22.3 ± 1.0 mV  (k = 
7.6 ± 0.5 mV; n=7) and for WT+T634S of -21.4 ± 2.9 mV ( k=6.9 ± 0.3 mV); n=5; P>0.05 for 
both V0.5 and k). Figure 1D shows overlain activation relations for WT and WT+T634S IhERG 
calculated from the experimentally obtained values. Collectively, the data in Figures 1B-D 
show that T634S led a marked loss of hERG channel function over a wide range of 
experimental voltages, without a significant shift in voltage-dependent activation of IhERG. 
Supplemental experiments employing a single voltage command (to +20 mV) were used to 
evaluate effects of the T634S mutation on WT+T634S IhERG deactivation. This followed a 
biexponential time-course under both conditions; the proportion of deactivating current 
fitted with fast (τf) and slow (τS) time-constants was similar between the two conditions. 
However, there was a modest increase in both τf ( from 183.8 ± 26.0 ms; n=10 to 386.6 ± 
95.3 ms; n=9; P<0.05) and τS (from 1333 ± 145 ms; n=10 to 2522 ± 491 ms; n=9; P<0.05). 
Thus, the dominant effect of the T634S mutation was suppression of IhERG magnitude, with a 
modest slowing of deactivation time-course. 
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3.2 Evaluation of functional consequences of the T634S mutation 
The action potential (AP) voltage-clamp technique enables ionic currents to be elicited by a 
physiological waveform and therefore exhibit a physiological time-course and voltage-
dependence. Figure 2A shows the mean (±SEM) profile of WT IhERG  and WT+T634S IhERG 
during an applied ventricular AP voltage command, as utilized previously [14]. WT IhERG 
increased progressively through the AP plateau, peaking just before the rapid terminal phase 
of repolarization (cf [19-22]). WT+T634S IhERG showed a similar profile to WT IhERG, but with 
current suppressed throughout the AP command. The voltage at which IhERG was maximal 
during repolarization lay between -30 and -40 mV as previously reported [19-22]) and did 
not differ between WT and WT+T634S conditions (Figure 2B).   
The difference between WT and WT+T634S peak IhERG in Figure 2A represents a reduction of 
~57 % in peak repolarizing current.  In order to evaluate consequences of the reduction in 
functional IhERG on ventricular repolarization, we investigated effects of reduction of IKr by 
this proportion in a human ventricular myocyte model [15]. Figure 2C shows epicardial 
ventricular APs under control conditions and with decreased IKr. The reduction in IKr (Figure 
2D), simulating the effect of the T634S mutation (under heterozygotic conditions), led to a 
lengthening of AP duration at 90% repolarization (APD90) from 263 ms to 297 ms (a 34 ms 
lengthening in APD90). Similar simulations were performed for midmyocardial and 
endocardial cell models (not shown), with respective APD90 prolongation observed in 
midmyocardial and endocardial AP models from 329 to 372 ms (a 43 ms prolongation) and 
263 to 305 ms (a 42 ms prolongation). The difference between epicardial and midmyocardial 
APD90 (a measure of repolarisation heterogeneity) in control was 66 ms and with IKr 
reduction was 75 ms. Thus, a reduction in IKr commensurate with the effect of the T634S 
mutation under heterozygous conditions led both to APD90 prolongation and augmented 
heterogeneity of repolarization between epicardial and midmyocardial cell models. 
Augmented dispersion of repolarization has been observed in experimental models of LQT2 
(e.g. [23; 24]) and may produce a substrate favourable to re-entrant arrhythmia. 
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3.3 Impairment of hERG channel trafficking by the T634S mutation 
Figure 3A-C shows the methodology (Figure 3Ai, Aii see also ‘Methods’) for and 
representative examples of hERG cell surface and total cell expression as analysed using LI-
COR® based On/In-Cell Western assays. Each condition shown was repeated in triplicate and 
the entire assay was repeated on at least 3 separate occasions for all conditions. Visual 
inspection of Figure 3Bi shows clear reductions in cell surface expression compared to WT 
for each of WT+T634S and T634S alone. Figure 3Bii shows mean (±SEM) normalized data for 
‘On-Cell’ cell surface expression. For T634S alone, cell surface expression was greatly 
reduced (by 67.9%; 0.17 ± 0.02 arbitrary fluorescent units (x 10-7)) compared to that of the 
WT channel (0.53 ± 0.03 units), with co-expression of WT+T634S producing an intermediate 
level of cell surface expression of 0.32±0.02 units, equating to a 39% reduction (both T634S 
conditions were significantly lower than those for the WT channel; P< 0.001). Figure 3Ci 
shows representative images of ‘In-Cell’ total cell hERG channel expression for the 
conditions shown in Figure 3Aii. There was no significant difference in total ‘In-Cell’ hERG 
channel expression between WT and mutant conditions. Taken collectively, these data 
indicate that T634S containing channels are synthesized, but not effectively transported to 
the cell surface membrane. This finding is consistent with an earlier observation that the 
T634I mutation reduces the amount of mature (fully glycosylated) hERG, indicative of 
defective trafficking [6].  
Some hERG trafficking deficient mutations are amenable to pharmacological rescue ([4; 6]).  
Accordingly, we evaluated whether or not the cell surface expression level of T634S 
containing channel complexes could be rescued by incubation with 5 µM E-4031. Figure 3Bi 
and Ci show representative images of WT, WT+T634S and T634S transfected cells in the 
absence and presence of E-4031 whilst Figure 3Bii and 3Cii incorporates the corresponding 
mean data. Pretreatment of T634S transfected cells with E-4031 led to a substantial increase 
in channel surface expression, under conditions mimicking both heterozygotic and 
homozygotic expression. Surface expression of WT hERG in E-4031 treated cells exceeded 
that of WT hERG in untreated cells (see Figure 3Bii), whilst the surface expression level of 
WT+T634S channels (0.76±0.02 units) was also substantially increased compared to that 
without E-4031 and that for T634S alone was more than doubled (from: 0.17±0.02 units to  
0.39±0.02 units after E-4031; P<0.0001). We also tested lumacaftor, a CFTR F508del 
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mutation corrector [18] in cystic fibrosis, that has recently been reported to exert beneficial 
effects on some hERG trafficking LQT2 mutants [25]. Surface expression of T634S in 5 µM 
lumacaftor treated cells did not differ from that in vehicle (DMSO) controls (Figure 3Bii). 
Thus, 24 hours exposure to E-4031 but not lumacaftor acted to rescue surface expression of 
T634S. In order to determine whether incubation with E-4031 also led to an increase in 
expression of functional hERG channels, additional experiments were performed in which 
IhERG was elicited using a depolarizing command to +20 mV. Figures 4Ai and Aii show example 
traces of recordings from T634S transfected cells without (Figure 4Ai) and following (Figure 
4Aii) 24 hrs of E-4031 preincubation. In the absence of E-4031 treatment, there was an 
absence of the resurgent tail current that is characteristic of IhERG. By contrast, in E-4031 
pretreated cells significant IhERG was elicited with a large deactivating IhERG tail. Figure 4B 
compares mean IhERG tail density, showing the very large increase in tail current in E-4031 
pretreated cells. Taken together with the data in Figure 3, both surface protein and 
electrophysiological measurements indicated that functional rescue of T634S channels by E-
4031 occurred. 
 
3.4 Conclusions – results in context 
The positional conservation between different K+ channels of a threonine residue at T634 in 
hERG (Figure 1A) and also of hydrogen bonding between this threonine and a glutamate 
residue at the top of the S5 helix [11] indicate that T634 is located in a functionally 
important region of the hERG channel pore.  It is notable that mutations of the analogous 
residue (T322  T322A or T322M) in KCNQ1 channels have been linked to the LQT1 form of 
LQTS, by causing dominant-negative suppression of KCNQ1+KCNE1 (“IKs”) current [26]. 
Mutations to nearby residues in hERG have been associated with LQTS [27] and the T634I 
and T634A mutations at the same position in the hERG protein have previously been 
associated with LQT2 [6; 12]. However, the present study is both the first to be conducted on 
the T634S mutation and the first to contain an electrophysiological characterization of any 
missense mutation to this residue. It is also the first to directly measure mutation effects at 
this position on surface expression rather than using mature channel glycosylation as a 
surrogate marker of surface expression [6]. A combination of similar approaches to those 
adopted here has recently been shown in a large-scale study to discriminate effectively 
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between benign and pathogenic hERG variants [9]. The effect of the T634S mutation on IhERG 
deactivation kinetics here was mild and our AP clamp data show that the timing of 
WT+T634S IhERG during the AP was unaffected by the mutation although current amplitude 
was markedly reduced. Our findings unambiguously demonstrate that the T634S mutation is 
detrimental to hERG channel trafficking but not synthesis. This results in a reduction in IKr 
under conditions mimicking heterozygous expression that is sufficient to lead to significant 
ventricular action potential prolongation and, by extension, potentially to an LQT2 
phenotype. T634S can therefore be categorized as a ‘Class 2’ (i.e. trafficking) mutation [4]. 
Under homozygous expression conditions T634I was previously reported to be an 
uncorrectable trafficking deficient mutation [6]. It is interesting, therefore, that in the 
present study E-4031 incubation improved T634S trafficking both under WT-mutant co-
expression conditions and when the mutation was studied alone. This may suggest that the 
trafficking dysfunction with T634S is more pharmacologically tractable than is that caused by 
T634I. However, as the methodologies for evaluating surface expression differ between the 
earlier study and our own [6], such comparison must be made with caution.   
It is important to note that whilst the approaches adopted in this study provide direct insight 
into mutation-induced channel dysfunction, they cannot provide insight into clinical 
penetrance of a mutation, nor do they supplant the need for careful characterization of a 
carrier’s ECG phenotype. However, it is striking that even amongst carriers of LQT2 
mutations with normal rate corrected QT (QTc) intervals, men carrying hERG pore mutations 
have a higher risk of cardiac events than those carrying non-pore mutations (hazard ratio 
6.01) [28]. This, in turn, highlights the utility of functional characterization of VUS located in 
the pore region of the hERG channel, so that clear functional and biochemical information 
can be available for consideration by clinical decision-makers.  
 
Acknowledgements:  TheˑauthorsˑacknowledgeˑresearchˑfundingˑfromˑtheˑBritish Heart 
Foundation (PG/17/89/33414; PG/17/77/33125) and DrˑClaire Turner, RoyalˑDevon and 
Exeter NHS Foundation Trust. 
 
  
For submission to BBRC 
 
12 
 
References 
 
 [1] M.C.Trudeau, J.W.Warmke, B.Ganetzky, G.A.Robertson, HERG, an inward rectifier in 
the voltage-gated potassium channel family Science 269, (1995) 92-95. 
 [2] M.C.Sanguinetti, C.Jiang, M.E.Curran, M.T.Keating, A mechanistic link between an 
inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium 
channel Cell 81, (1995) 299-307. 
 [3] M.C.Sanguinetti, M.Tristani-Firouzi, hERG potassium channels and cardiac arrhythmia 
Nature 440, (2006) 463-469. 
 [4] J.L.Smith, C.L.Anderson, D.E.Burgess, C.S.Elayi, C.T.January, B.P.Delisle, Molecular 
pathogenesis of long QT syndrome type 2 J.Arrhythm. 32, (2016) 373-380. 
 [5] J.C.Hancox, D.G.Whittaker, C.Du, A.G.Stuart, H.Zhang, Emerging therapeutic targets in 
the short QT syndrome Expert.Opin.Ther.Targets. 22, (2018) 439-451. 
 [6] C.L.Anderson, C.E.Kuzmicki, R.R.Childs, C.J.Hintz, B.P.Delisle, C.T.January, Large-scale 
mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT 
syndrome Nat.Commun. 5, (2014) 5535.  
 [7] A.J.Moss, W.Zareba, E.S.Kaufman, E.Gartman, D.R.Peterson, J.Benhorin, J.A.Towbin, 
M.T.Keating, S.G.Priori, P.J.Schwartz, G.M.Vincent, J.L.Robinson, M.L.Andrews, 
C.Feng, W.J.Hall, A.Medina, L.Zhang, Z.Wang, Increased risk of arrhythmic 
events in long-QT syndrome with mutations in the pore region of the human 
ether-a-go-go-related gene potassium channel Circulation 105, (2002) 794-799. 
 [8] W.Shimizu, A.J.Moss, A.A.Wilde, J.A.Towbin, M.J.Ackerman, C.T.January, D.J.Tester, 
W.Zareba, J.L.Robinson, M.Qi, G.M.Vincent, E.S.Kaufman, N.Hofman, T.Noda, 
S.Kamakura, Y.Miyamoto, S.Shah, V.Amin, I.Goldenberg, M.L.Andrews, 
S.McNitt, Genotype-phenotype aspects of type 2 long QT syndrome 
J.Am.Coll.Cardiol. 54, (2009) 2052-2062. 
 [9] C.A.Ng, M.D.Perry, W.Liang, N.J.Smith, B.Foo, A.Shrier, G.L.Lukacs, A.P.Hill, 
J.I.Vandenberg, High-throughput phenotyping of heteromeric human ether-a-
go-go-related gene potassium channel variants can discriminate pathogenic 
from rare benign variants. Heart Rhythm 17, (2020) 492-500. 
[10] C.G.Vanoye, A.L.George, Jr., Decoding KCNH2 variants of unknown significance Heart 
Rhythm. 17, (2020), 501-502. 
[11] S.L.Wilson, C.E.Dempsey, J.C.Hancox, N.V.Marrion, Identification of a proton sensor 
that regulates conductance and open time of single hERG channels Sci.Rep. 9, 
(2019) 19825. 
[12] M.Yoshinaga, Y.Kucho, J.Sarantuya, Y.Ninomiya, H.Horigome, H.Ushinohama, 
W.Shimizu, M.Horie, Genetic characteristics of children and adolescents with 
For submission to BBRC 
 
13 
 
long-QT syndrome diagnosed by school-based electrocardiographic screening 
programs Circ.Arrhythm.Electrophysiol. 7, (2014) 107-112. 
[13] E.K.El Emam, S.Rodgers, B.Malin, Anonymising and sharing individual patient data BMJ 
350, (2015) h1139. 
[14] D.Melgari, K.E.Brack, C.Zhang, Y.Zhang, A.El Harchi, J.S.Mitcheson, C.E.Dempsey, 
G.A.Ng, J.C.Hancox, hERG potassium channel blockade by the HCN channel 
inhibitor bradycardic agent ivabradine J.Am.Heart Assoc. 4, (2015). 
[15] T.O'Hara, L.Virag, A.Varro, Y.Rudy, Simulation of the undiseased human cardiac 
ventricular action potential: model formulation and experimental validation 
PLoS.Comput.Biol. 7, (2011) e1002061. 
[16] E.Ficker, A.T.Dennis, L.Wang, A.M.Brown, Role of the cytosolic chaperones Hsp70 and 
Hsp90 in maturation of the cardiac potassium channel HERG Circ.Res. 92, 
(2003) e87-100. 
[17] P.M.Apaja, B.Foo, T.Okiyoneda, W.C.Valinsky, H.Barriere, R.Atanasiu, E.Ficker, 
G.L.Lukacs, A.Shrier, Ubiquitination-dependent quality control of hERG K+ 
channel with acquired and inherited conformational defect at the plasma 
membrane Mol.Biol.Cell 24, (2013) 3787-3804. 
[18] X.Meng, Y.Wang, X.Wang, J.A.Wrennall, T.L.Rimington, H.Li, Z.Cai, R.C.Ford, 
D.N.Sheppard, Two Small Molecules Restore Stability to a Subpopulation of the 
Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant 
Disease-causing Mutation J.Biol.Chem. 292, (2017) 3706-3719. 
[19] M.J.McPate, R.S.Duncan, J.T.Milnes, H.J.Witchel, J.C.Hancox, The N588K-HERG K+ 
channel mutation in the 'short QT syndrome': mechanism of gain-in-function 
determined at 37oC. Biochem.Biophys.Res.Comm 334, (2005) 441-449. 
[20] Y.H.Zhang, C.K.Colenso, R.B.Sessions, C.E.Dempsey, J.C.Hancox, The hERG K(+) channel 
S4 domain L532P mutation: characterization at 37 degrees C Biochim.Biophys 
Acta 1808, (2011) 2477-2487. 
[21] J.C.Hancox, A.J.Levi, H.J.Witchel, Time course and voltage dependence of expressed 
HERG current compared with native 'rapid' delayed rectifier K current during 
the cardiac ventricular action potential. Pflugers Archiv - European Journal of 
Physiology 436, (1998) 843-853. 
[22] Z.Zhou, Q.Gong, B.Ye, Z.Fan, J.C.Makielski, G.A.Robertson, C.T.January, Properties of 
HERG channels stably expressed in HEK 293 cells studied at physiological 
temperature. Biophys.J. 74, (1998) 230-241. 
[23] W.Shimizu, C.Antzelevitch, Cellular basis for long QT, transmural dispersion of 
repolarization, and torsade de pointes in the long QT syndrome 
J.Electrocardiol. 32 Suppl, (1999) 177-184. 
For submission to BBRC 
 
14 
 
[24] F.G.Akar, K.R.Laurita, D.S.Rosenbaum, Cellular basis for dispersion of repolarization 
underlying reentrant arrhythmias J Electrocardiol. 33 Suppl, (2000) 23-31. 
[25] A.Mehta, C.J.A.Ramachandra, P.Singh, A.Chitre, C.H.Lua, M.Mura, L.Crotti, P.Wong, 
P.J.Schwartz, M.Gnecchi, W.Shim, Identification of a targeted and testable 
antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific 
cellular model Eur.Heart J. 39, (2018) 1446-1455. 
[26] D.E.Burgess, D.C.Bartos, A.R.Reloj, K.S.Campbell, J.N.Johnson, D.J.Tester, 
M.J.Ackerman, V.Fressart, I.Denjoy, P.Guicheney, A.J.Moss, S.Ohno, M.Horie, 
B.P.Delisle, High-risk long QT syndrome mutations in the Kv7.1 (KCNQ1) pore 
disrupt the molecular basis for rapid K(+) permeation Biochem 51, (2012) 9076-
9085. 
[27] C.A.Satler, M.R.Vesely, P.Duggal, G.S.Ginsburg, A.H.Beggs, Multiple different missense 
mutations in the pore region of HERG in patients with long QT syndrome 
Hum.Genet. 102, (1998) 265-272. 
[28] P.G.Platonov, S.McNitt, B.Polonsky, S.Z.Rosero, V.Kutyifa, A.Huang, A.J.Moss, 
W.Zareba, Risk Stratification of Type 2 Long-QT Syndrome Mutation Carriers 
With Normal QTc Interval: The Value of Sex, T-Wave Morphology, and 
Mutation Type Circ.Arrhythm.Electrophysiol. 11, (2018) e005918. 
 
  
For submission to BBRC 
 
15 
 
Figure Legends 
Figure 1: Sequence alignments and Current-voltage (I-V) relations for WT, T643S and 
WT+T634S hERG  
A) Sequence alignments between hERG (KCNH2), EAG (KCNH1), bacterial (MthK, KcsA, KvAP) 
and other human (KCNA2-encoded Kv2.1, KCNQ1, and KCND3-encoded Kv4.3) potassium 
channels, showing conservation across all these channels of the threonine (T) residue at 
position 634 in hERG. 
B) Representative current (I
hERG
) traces for Bi: WT, Bii: WT+T634S and Biii: T634S hERG. Voltage 
protocol was comprised of 2s depolarising commands applied at 10 mV increments between 
−40 mV and +60 mV, from -80 mV (start-to-start interval of 12 s). Only selected traces are 
shown for clarity. The corresponding voltage commands are indicated to the right of currents 
in Bi and Bii.  
C): Mean I-V relations for tail current of WT, T634S, and the WT+T634S I
hERG 
following each 
command pulse. The plots for WT and WT+T634 hERG were fitted with a modified Boltzmann 
equation. 
D): Derived activation curve for WT (in blue) and WT and T634S (in red). V
0.5
 for WT: -22.3 ± 
1.0 mV, k: 7.6 ± 0.5 (n=7). V
0.5
 for WT+T634S: -21.4 ± 2.9 mV, k: 6.9 ± 0.3 (n=5). Asterisks denote 
significant difference from corresponding value for WT IhERG (* =P<0.05; ** P<0.01; *** 
P<0.001; ****P<0.0001). 
 
Figure 2:ˑI
hERG
ˑduringˑventricularˑactionˑpotentials:ˑAPˑclampˑandˑAP simulation.  
A) Means ± SEM I
hERG
 for WT (n = 5) and WT+T634S conditions (n = 5). Corresponding action 
potential (AP) command is superimposed on the plotted normalised currents. Co-expression 
of WT and T634S suppressed current compared to WT hERG alone. 
B) Bar chart comparing the voltage (for WT and WT+T634S) where peak I
hERG
 occurred during 
AP repolarisation, WT (n = 5) and WT+T634S (n = 5; P>0.05 versus WT, unpaired t test).  
C)   Epicardial action potentials from the O’Hara-Rudy model generated under control 
conditions at 1Hz stimulation frequency and with reduced IKr (gKr reduced by 57.1 %).   
D)  Corresponding IKr records during the control and reduced IKr APs shown in C.  
 
Figure 3:  Effect of T634S mutation on hERG channel trafficking and potential for 
pharmacological rescue 
Ai,ii) Schematic diagram showing experimental setup for LI-COR® based Cell Surface (CSA) 
(‘On-Cell’) and Total cellular hERG expression (Total) (‘In-Cell’) Western assays. 
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B) ‘On-Cell’ Cell Surface hERG expression. Upper panel Bi shows a representative Cell Surface 
(CSA) (‘On-Cell’) Western assay (green channel (800); upper panel). To determine cell number, 
cells were stained using WGA-680 (red channel (700); middle panel) and the two channels are 
merged in the lower panel. Bii: Quantified Cell Surface ‘On-Cell’ hERG expression levels of WT, 
T634S, and co-expression of WT+T634S. A 24 hour pretreatment with 5 µM E-4031 
significantly increased the cell surface expression level of WT, T634S and T634S+WT. In 
contrast, a 24 hour pretreatment with 5 µM lumacaftor did not lead to significant changes in 
cell surface expression when compared to vehicle control (treatment with DMSO alone).  
C) ‘In-Cell’ Total cellular hERG expression. Upper panel Ci shows a representative Total cellular 
(Total) (‘In-Cell’) Western assay (green channel (800); upper panel). To determine cell number, 
cells were stained using WGA-680 (red channel (700); middle panel) and the two channels are 
merged in the lower panel. Cii: Quantified Total ‘In-Cell’ cellular hERG expression levels of WT, 
T634S, and co-expression of WT+T634S in control and 24 hour pretreatment with 5 µM E-
4031, 5 µM lumacaftor or vehicle control (DMSO treatment was included as a vehicle control 
for lumacaftor). No significant differences in Total cellular hERG channel expression levels 
were detected between any of the groups.  
Statistical analyses were performed using One Way ANOVA and Bonferroni’s multiple 
comparison; ****= P<0.0001 & ***= P<0.001. For references to colour, see online version of 
the paper. 
 
Figure 4:  Functional rescue of T634S IhERG 
(Ai,Aii)  Upper traces are representative examples of current elicited by voltage protocol 
shown as lower traces for T634S transfected cell without (Ai) and following (Aii) 24 hours 
incubation in 5 µM E-4031. In each case, recordings were made following a 1-2 hour washout 
of E-4031. 
(B) Mean amplitude of outward current on repolarization to -40 mV for T634S transfected 
cells that were not exposed to E-4031 (- E-4031; n=6) and following E-4031 pre-treatment (+ 
E-4031; n=8)  
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